These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 18288998)

  • 1. Anticancer compounds as leishmanicidal drugs: challenges in chemotherapy and future perspectives.
    Fuertes MA; Nguewa PA; Castilla J; Alonso C; Pérez JM
    Curr Med Chem; 2008; 15(5):433-9. PubMed ID: 18288998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
    Gonzalez-Fajardo L; Fernández OL; McMahon-Pratt D; Saravia NG
    PLoS Negl Trop Dis; 2015 May; 9(5):e0003820. PubMed ID: 26024228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1.
    Mandal G; Mandal S; Sharma M; Charret KS; Papadopoulou B; Bhattacharjee H; Mukhopadhyay R
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003500. PubMed ID: 25714343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meglumine Antimoniate (Glucantime) Causes Oxidative Stress-Derived DNA Damage in BALB/c Mice Infected by Leishmania (Leishmania) infantum.
    Moreira VR; de Jesus LCL; Soares RP; Silva LDM; Pinto BAS; Melo MN; Paes AMA; Pereira SRF
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment.
    Vélez ID; Colmenares LM; Muñoz CA
    Rev Inst Med Trop Sao Paulo; 2009; 51(4):231-6. PubMed ID: 19739006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-substituted quinoline alkaloids as potential antileishmanial drugs.
    Fournet A; Barrios AA; Muñoz V; Hocquemiller R; Cavé A; Bruneton J
    Antimicrob Agents Chemother; 1993 Apr; 37(4):859-63. PubMed ID: 8494383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
    Borborema SE; Schwendener RA; Osso JA; de Andrade HF; do Nascimento N
    Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promising therapeutic targets for antileishmanial drugs.
    Werbovetz KA
    Expert Opin Ther Targets; 2002 Aug; 6(4):407-22. PubMed ID: 12223057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate.
    Perez-Franco JE; Cruz-Barrera ML; Robayo ML; Lopez MC; Daza CD; Bedoya A; Mariño ML; Saavedra CH; Echeverry MC
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004739. PubMed ID: 27243811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
    Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
    AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leishmaniasis: current treatment and prospects for new drugs and vaccines.
    Kedzierski L; Sakthianandeswaren A; Curtis JM; Andrews PC; Junk PC; Kedzierska K
    Curr Med Chem; 2009; 16(5):599-614. PubMed ID: 19199925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance.
    Dzamitika SA; Falcão CA; de Oliveira FB; Marbeuf C; Garnier-Suillerot A; Demicheli C; Rossi-Bergmann B; Frézard F
    Chem Biol Interact; 2006 Apr; 160(3):217-24. PubMed ID: 16524568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate.
    Vouldoukis I; Rougier S; Dugas B; Pino P; Mazier D; Woehrlé F
    Vet Parasitol; 2006 Jan; 135(2):137-46. PubMed ID: 16242844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined effect of the essential oil from Chenopodium ambrosioides and antileishmanial drugs on promastigotes of Leishmania amazonensis.
    Monzote L; Montalvo AM; Scull R; Miranda M; Abreu J
    Rev Inst Med Trop Sao Paulo; 2007; 49(4):257-60. PubMed ID: 17823757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meglumine antımoniate-TiO2@Ag nanoparticle combinations reduce toxicity of the drug while enhancing its antileishmanial effect.
    Abamor ES; Allahverdiyev AM; Bagirova M; Rafailovich M
    Acta Trop; 2017 May; 169():30-42. PubMed ID: 28111133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of antimonial therapy for canine leishmaniasis on antibody titer.
    Amusategui I; Sainz A; Tesouro MA
    Ann N Y Acad Sci; 1998 Jun; 849():444-6. PubMed ID: 9668509
    [No Abstract]   [Full Text] [Related]  

  • 17. [Current situation and future of antileishmanial therapy in Colombia].
    Soto J; Soto P
    Biomedica; 2006 Oct; 26 Suppl 1():194-206. PubMed ID: 17361855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New delivery strategies for the old pentavalent antimonial drugs.
    Frézard F; Demicheli C
    Expert Opin Drug Deliv; 2010 Dec; 7(12):1343-58. PubMed ID: 21029028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy of leishmaniasis in India.
    Thakur CP
    Indian J Pediatr; 1987; 54(1):7-10. PubMed ID: 3030933
    [No Abstract]   [Full Text] [Related]  

  • 20. Application of nanotechnology in treatment of leishmaniasis: A Review.
    Akbari M; Oryan A; Hatam G
    Acta Trop; 2017 Aug; 172():86-90. PubMed ID: 28460833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.